| Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy JT Brown, JR Bishop, K Sangkuhl, EL Nurmi, DJ Mueller, JC Dinh, ... Clinical Pharmacology & Therapeutics 106 (1), 94-102, 2019 | 186 | 2019 |
| Ten years’ experience with the CYP2D6 activity score: a perspective on future investigations to improve clinical predictions for precision therapeutics A Gaedigk, JC Dinh, H Jeong, B Prasad, JS Leeder Journal of personalized medicine 8 (2), 15, 2018 | 138 | 2018 |
| Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo BS Raccor, AJ Claessens, JC Dinh, JR Park, DS Hawkins, SS Thomas, ... Drug Metabolism and Disposition 40 (1), 54-63, 2012 | 59 | 2012 |
| Molecular regulation of bile acid homeostasis S Choudhuri, CD Klaassen Drug Metabolism and Disposition 50 (4), 425-455, 2022 | 28 | 2022 |
| Characterization of atomoxetine biotransformation and implications for development of PBPK models for dose individualization in children JC Dinh, RE Pearce, L Van Haandel, A Gaedigk, JS Leeder Drug Metabolism and Disposition 44 (7), 1070-1079, 2016 | 26 | 2016 |
| Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: knowledge deficits and prospects for future research T Lewis, J Dinh, JS Leeder Clinical Pharmacology & Therapeutics 98 (3), 309-320, 2015 | 24 | 2015 |
| Is this the end for ranitidine? NDMA presence continues to confound JA Wagner, JC Dinh, JR Lightdale, BD Gold, JM Colombo Clinical and Translational Science 14 (4), 1197, 2021 | 16 | 2021 |
| Ontogeny of scaling factors for pediatric physiology-based pharmacokinetic modeling and simulation: microsomal protein per gram of liver JS Leeder, JC Dinh, A Gaedigk, VS Staggs, B Prasad, RE Pearce Drug Metabolism and Disposition 50 (1), 24-32, 2022 | 9 | 2022 |
| Description of an innovative pediatric individualized therapeutics clinic: working toward precision drug therapy TL Sandritter, JC Dinh, JA Wagner, JA Lowry Children 6 (2), 35, 2019 | 6 | 2019 |
| Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity P Zubiaur, P Soria‐Chacartegui, EC Boone, B Prasad, J Dinh, WY Wang, ... Clinical Pharmacology & Therapeutics 114 (5), 1033-1042, 2023 | 5 | 2023 |
| The respective roles of CYP3A4 and CYP2D6 in the metabolism of pimozide to established and novel metabolites BD Chapron, JC Dinh, PC Toren, A Gaedigk, JS Leeder Drug Metabolism and Disposition 48 (11), 1113-1120, 2020 | 5 | 2020 |
| The impact of the CYP2D6 “enhancer” single nucleotide polymorphism on CYP2D6 activity JC Dinh, EC Boone, VS Staggs, RE Pearce, WY Wang, R Gaedigk, ... Clinical Pharmacology & Therapeutics 111 (3), 646-654, 2022 | 4 | 2022 |
| Pediatric clinical endpoint and pharmacodynamic biomarkers: limitations and opportunities JC Dinh, CM Hosey-Cojocari, BL Jones Pediatric Drugs 22, 55-71, 2020 | 3 | 2020 |
| Cardiac disease alters myocardial tissue levels of epoxyeicosatrienoic acids and key proteins involved in their biosynthesis and degradation T Aliwarga, JC Dinh, S Heyward, B Prasad, SA Gharib, RN Lemaitre, ... International Journal of Molecular Sciences 23 (20), 12433, 2022 | 2 | 2022 |
| PROSPECTIVE VALIDATION OF A POPULATION PHARMACOKINETIC MODEL DERIVED DOSING ALGORITHM OF ATOMOXETINE, A CYP2D6 MODEL SUBSTRATE. JC Dinh, BT Black, BJ Matzuka, KT Gibson, L Van Haandel, A Gaedigk, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S29-S30, 2018 | 2 | 2018 |
| Principles of drug metabolism 3: enzymes and tissues BS Raccor, AM Teitelbaum, JC Dinh, RA Totah Elsevier, 2014 | 2 | 2014 |
| Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities J Dinh, TN Johnson, M Grimstein, T Lewis Pharmaceutics 15 (11), 2579, 2023 | 1 | 2023 |
| Aggregate bottom-up PBPK models for drug exposure individualization JC Dinh, B Prasad, JS Leeder CLINICAL PHARMACOLOGY & THERAPEUTICS 101 (S 1), S7-S7, 2017 | 1 | 2017 |
| Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model M Codaccioni, RL Southall, J Dinh, TN Johnson The Journal of Clinical Pharmacology, 2024 | | 2024 |
| Managing Drug Interactions Involving the Over-the-Counter Opioid Loperamide through Physiologically Based Pharmacokinetic Modeling Z Zhou, M Li, P Zhao, J Dinh, M Paine Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
